Humira, Enbrel and Remicade are NICE choices for psoriatic arthritis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has given a preliminary green light to treating some psoriatic arthritis patients with Abbott's Humira (adalimumab) and Wyeth's Enbrel (etanercept) as well as Merck & Co's Remicade (infliximab). The latter is only to be used if Humira and Enbrel are unsuitable.